Last reviewed · How we verify

Mineralocorticoid receptor antagonist potassium-canrenoate — Competitive Intelligence Brief

Mineralocorticoid receptor antagonist potassium-canrenoate (Mineralocorticoid receptor antagonist potassium-canrenoate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineralocorticoid receptor antagonist. Area: Cardiovascular.

phase 3 Mineralocorticoid receptor antagonist Mineralocorticoid receptor (MR) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Mineralocorticoid receptor antagonist potassium-canrenoate (Mineralocorticoid receptor antagonist potassium-canrenoate) — University College, London. Potassium-canrenoate blocks mineralocorticoid receptors to reduce sodium reabsorption and potassium excretion in the kidney, lowering blood pressure and reducing fluid retention.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mineralocorticoid receptor antagonist potassium-canrenoate TARGET Mineralocorticoid receptor antagonist potassium-canrenoate University College, London phase 3 Mineralocorticoid receptor antagonist Mineralocorticoid receptor (MR)
Eplerenone (Night-time) Eplerenone (Night-time) Vanderbilt University Medical Center marketed Selective aldosterone antagonist (mineralocorticoid receptor antagonist) Mineralocorticoid receptor (MR)
Ambrisentan plus Spironolactone Ambrisentan plus Spironolactone Brigham and Women's Hospital marketed Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor
Mineralocorticoid Receptor Antagonist Mineralocorticoid Receptor Antagonist Cheng-Hsin General Hospital marketed Mineralocorticoid receptor antagonist Mineralocorticoid receptor (MR)
Finerenone (BAY 94-8862) Finerenone (BAY 94-8862) University Medical Center Groningen marketed Non-steroidal mineralocorticoid receptor antagonist Mineralocorticoid receptor (MR)
Propranolol - Spironolactone Propranolol - Spironolactone University Hospital, Angers marketed Beta-blocker and mineralocorticoid receptor antagonist combination Beta-adrenergic receptors (propranolol); mineralocorticoid receptor (spironolactone)
ACEI / ARB+finerenone ACEI / ARB+finerenone Capital Institute of Pediatrics, China marketed ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineralocorticoid receptor antagonist class)

  1. Bayer · 1 drug in this class
  2. Cheng-Hsin General Hospital · 1 drug in this class
  3. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  4. Kowa Company, Ltd. · 1 drug in this class
  5. University College, London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mineralocorticoid receptor antagonist potassium-canrenoate — Competitive Intelligence Brief. https://druglandscape.com/ci/mineralocorticoid-receptor-antagonist-potassium-canrenoate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: